Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Withdrawn 3Completed 3Terminated 2

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Other 3

Conditions

Mucositis 3Hematologic Neoplasms 3Graft vs Host Disease 1

Interventions

Cyclophosphamide 129Cisplatin 119Radiotherapy 115pembrolizumab 111Carboplatin 97Paclitaxel 96Gemcitabine 96Magnetic Resonance Spectroscopy 80Nivolumab 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Biopsy 53Doxorubicin 52fludarabine 51Drug Therapy 45durvalumab 44Cytarabine 44Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Surveys and Questionnaires 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × angiotensin I (1-7) × Clear all
NCT01554254 2016-08-31

Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation

Tarix Pharmaceuticals

Phase 2 Withdrawn
OtherOther hematologic neoplasm

Hematologic Neoplasms, Mucositis

NCT01882374 2016-08-31

Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation

Tarix Pharmaceuticals

Phase 2 Withdrawn
OtherOther hematologic neoplasm

Hematologic Neoplasms, Mucositis

NCT01882387 2016-08-31

Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

Tarix Pharmaceuticals

Phase 2 Withdrawn
OtherOther hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡